SLN vs. ACAD, BHC, ARVN, DCPH, MRVI, RYTM, GERN, VERA, AMPH, and AGIO
Should you be buying Silence Therapeutics stock or one of its competitors? The main competitors of Silence Therapeutics include ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Arvinas (ARVN), Deciphera Pharmaceuticals (DCPH), Maravai LifeSciences (MRVI), Rhythm Pharmaceuticals (RYTM), Geron (GERN), Vera Therapeutics (VERA), Amphastar Pharmaceuticals (AMPH), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical preparations" industry.
ACADIA Pharmaceuticals (NASDAQ:ACAD) and Silence Therapeutics (NASDAQ:SLN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, community ranking, risk, profitability, valuation and earnings.
ACADIA Pharmaceuticals has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
ACADIA Pharmaceuticals currently has a consensus price target of $28.94, suggesting a potential upside of 91.64%. Silence Therapeutics has a consensus price target of $57.25, suggesting a potential upside of 172.75%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Silence Therapeutics is more favorable than ACADIA Pharmaceuticals.
In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 8 mentions for ACADIA Pharmaceuticals and 5 mentions for Silence Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.25 beat Silence Therapeutics' score of 0.21 indicating that Silence Therapeutics is being referred to more favorably in the news media.
ACADIA Pharmaceuticals received 852 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 73.53% of users gave Silence Therapeutics an outperform vote while only 72.96% of users gave ACADIA Pharmaceuticals an outperform vote.
Silence Therapeutics has lower revenue, but higher earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.
ACADIA Pharmaceuticals has a net margin of -0.21% compared to ACADIA Pharmaceuticals' net margin of -131.44%. Silence Therapeutics' return on equity of -0.41% beat ACADIA Pharmaceuticals' return on equity.
Summary
ACADIA Pharmaceuticals and Silence Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Silence Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silence Therapeutics Competitors List
Related Companies and Tools
